Market Cap: 22.6441B; Large Cap
P/E Ratio: N/A; Fwd: 16.37
EPS (TTM): $-5.76
Div. Yield: N/A

IN

INSMNASDAQ— Insmed Inc Price & Analysis

Insmed Inc

HEALTHCARE — BIOTECHNOLOGY

$103.38

-$1.09-1.04%

Market Cap: 22.6441B; Large Cap
P/E Ratio: N/A; Fwd: 16.37
EPS (TTM): $-5.76
Div. Yield: N/A

Technical Summary

RSI (14)48.42Neutral

SMA (50)$114.32Bearish

SMA (200)$152.52Bearish

MACD-3.2108Bullish

Bollinger$91.18 – $108.69Mid

Stochastic77.76Neutral

Theo Outlook

Insmed Inc (INSM) presents a bearish near-term thesis driven by persistent unprofitability, with a market capitalization of $22.41 billion, negative EPS of -$5.70, and no trailing P/E due to losses. Quarterly revenue growth of 229.6% YoY to $819.6 million TTM signals rapid top-line expansion, yet the forward P/E of 16.37 and negative operating margin of -65.5% highlight ongoing cash burn of $949 million EBITDA. Analysts maintain a strong buy consensus with a $197.05 target price, implying upside from current levels around the 50-day moving average of $115.19.

Key catalysts include potential product launches in rare disease therapies and market expansion in biotechnology, supported by 2.3x quarterly revenue growth momentum and analyst ratings of 5 strong buy and 17 buy. Earnings momentum is bolstered by the latest quarter ending March 31, 2026, with institutional ownership at 106.1% of float indicating confidence in pipeline advancement and geographic reach.

Risks center on regulatory hurdles for drug approvals, intense competition in rare disease biotech, and macroeconomic headwinds like rising interest rates affecting funding. Mitigations include diversified pipeline development, strong insider ownership of 0.52%, and a beta of 0.77 providing relative stability versus the broader market. Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.

Theo Outlook

Insmed Inc (INSM) presents a bearish near-term thesis driven by persistent unprofitability, with a market capitalization of $22.41 billion, negative EPS of -$5.70, and no trailing P/E due to losses. Quarterly revenue growth of 229.6% YoY to $819.6 million TTM signals rapid top-line expansion, yet the forward P/E of 16.37 and negative operating margin of -65.5% highlight ongoing cash burn of $949 million EBITDA. Analysts maintain a strong buy consensus with a $197.05 target price, implying upside from current levels around the 50-day moving average of $115.19.

Key catalysts include potential product launches in rare disease therapies and market expansion in biotechnology, supported by 2.3x quarterly revenue growth momentum and analyst ratings of 5 strong buy and 17 buy. Earnings momentum is bolstered by the latest quarter ending March 31, 2026, with institutional ownership at 106.1% of float indicating confidence in pipeline advancement and geographic reach.

Risks center on regulatory hurdles for drug approvals, intense competition in rare disease biotech, and macroeconomic headwinds like rising interest rates affecting funding. Mitigations include diversified pipeline development, strong insider ownership of 0.52%, and a beta of 0.77 providing relative stability versus the broader market. Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.

Company Overview

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Fundamental Snapshot

Revenue: 819.564M
EBITDA: -949.036M
Gross Profit: 670.484M
Operating Margin: -65.5%
Profit Margin: -144.4%
ROE: -294.5%
Book Value: $3.255
Beta: 0.774
52-Wk High: $212.75
52-Wk Low: $90.39
Avg Volume: 6.1247M
PEG Ratio: 1.092

Frequently Asked Questions

What is Insmed's business model?

Insmed Inc operates as a biopharmaceutical company focused on developing and commercializing therapies for rare and serious diseases. It generates revenue primarily through product sales in the biotechnology sector, with TTM revenue of $819.6 million and no dividend yield.

What are Insmed's main revenue sources?

Revenue comes from sales of approved therapies targeting rare diseases, with TTM revenue reaching $819.6 million and quarterly growth of 229.6% YoY. The company reports no dividend per share and relies on product commercialization rather than diversified streams.

What competitive advantages does Insmed have?

Trading Data

Open: $105.11
Previous Close: $104.47
Day Range: $102.59 – $108.14
Volume: 6.2501M
Shares Outstanding: 216.752M
Analyst Target: $197.05

Related Assets

Intuitive Surgical Inc

Vertex Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

$632.90

+2.06%

Get Deeper Analysis

Ask Theo anything about INSM — earnings, valuation, technicals, or portfolio fit.

Try HeyTheo Free

Company Overview

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Fundamental Snapshot

Revenue: 819.564M
EBITDA: -949.036M
Gross Profit: 670.484M
Operating Margin: -65.5%
Profit Margin: -144.4%
ROE: -294.5%
Book Value: $3.255
Beta: 0.774
52-Wk High: $212.75
52-Wk Low: $90.39
Avg Volume: 6.1247M
PEG Ratio: 1.092

Frequently Asked Questions

What is Insmed's business model?

Insmed Inc operates as a biopharmaceutical company focused on developing and commercializing therapies for rare and serious diseases. It generates revenue primarily through product sales in the biotechnology sector, with TTM revenue of $819.6 million and no dividend yield.

What are Insmed's main revenue sources?

Revenue comes from sales of approved therapies targeting rare diseases, with TTM revenue reaching $819.6 million and quarterly growth of 229.6% YoY. The company reports no dividend per share and relies on product commercialization rather than diversified streams.

What competitive advantages does Insmed have?

Insmed benefits from a specialized focus on rare diseases, a robust pipeline, and high institutional ownership at 106.1%. Its forward P/E of 16.37 and analyst target of $197.05 reflect perceived advantages in niche markets over broader competitors.

What are the key risks for INSM investors?

Key risks include ongoing losses with EPS of -$5.70, negative profit margin of -144.4%, and regulatory approval challenges. Macro headwinds and competition are mitigated by a low beta of 0.77 and strong analyst buy ratings totaling 22.

What is the growth outlook for Insmed?

Growth outlook is positive with 229.6% YoY revenue growth and a $197.05 analyst target price. The company trades near a 52-week high of $212.75, supported by pipeline catalysts despite current negative EPS and market cap of $22.41 billion.

IN